Kyruus Health
Bryan is a Partner at Venrock, joining the firm as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Coderyte, Intarcia, Kyruus and Tandem Diagnostics. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbes’ Midas List since 2008. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Kyruus Health
5 followers
Kyruus delivers leading enterprise provider search and scheduling solutions that help health systems match patients with the right providers across points of access. Powered by a robust provider data management platform, the ProviderMatch suite of applications - for consumers, access centers, & referring providers - enables health systems to enhance the patient experience and better align patient demand with network capacity.